SPARC KnockOut Mice, an Animal Model for Cataract Formation and Osteopenia

Inventor: Chin Howe

Tech ID: HC-95001

Description: Wistar researchers have developed a knockout mouse that does not express the gene for SPARC (secreted protein, acidic, and rich in cysteine). This protein, also known as osteonectin and MB-40 is an extracellular matrix glycoprotein that is produced by epithelial cells.

SPARC knockout mice develop cataracts and osteopenia as they mature. By 1.5 months of age these mice develop diffuse posterior cortical cataracts which progress towards the anterior cortex and are fully expressed as early as 3.5 months of age. As the mice mature, massive lens degradation occurs, leading to recruitment of inflammatory cells and triggering retinal detachments and adhesion of the iris to the lens.

By 2.5 months of age, SPARC knockout mice begin to show decreased bone mass, when measured by x-ray and morphometric analysis, compared to age-matched controls. This loss of bone mass progresses as the mice age, leading to severe osteopenia.

Applications and Advantages: SPARC knockout mice may be useful as an animal model for age-onset bone loss and cataract formation, two common pathologies associated with aging. The animals may be useful to develop or evaluate new diagnostic and therapeutic agents for these conditions.

Intellectual Property Status: US patent application is filed.

Licensing Opportunity: This technology is protected by U.S. patent 6,239,326 B1.

Key Words: Screening, therapeutic, diagnostic, disease model, cataract, osteoporosis, metabolic diseases

Contact:

Meryle J. Melnicoff
Director, Business Development
The Wistar Institute
3601 Spruce Street
Philadelphia, PA 19104
Phone: (215) 898-0049
Fax: (215) 573-2456
melnicoff@wistar.org

Last updated: Nov. 99